Kurume Medical Journal最新文献_第5页

Brown-Kurume Exchange Programs Have Developed Through Many Unexpected Encounters and Relationships. 布朗-久留米交流计划是在许多意想不到的邂逅和关系中发展起来的。

Kurume Medical Journal Pub Date : 2024-05-14 Epub Date: 2024-01-16 DOI: 10.2739/kurumemedj.MS6934007

Emiko Mizoguchi

引用次数: 0

Onasemnogene Abeparvovec Treatment after Nusinersen in an Infant with Spinal Muscular Atrophy Type 1. 一名 1 型脊髓性肌肉萎缩症婴儿在服用 Nusinersen 后接受 Onasemnogene Abeparvovec 治疗。

Kurume Medical Journal Pub Date : 2024-05-14 Epub Date: 2024-01-16 DOI: 10.2739/kurumemedj.MS6934008

Daiki Nanri, Kotaro Yuge, Kohei Goto, Takuro Kimura, Yukako Yae, Tatsuki Mizuochi, Ryosuke Sato, Tomoyo Itonaga, Tomoki Maeda, Yushiro Yamashita

{"title":"Onasemnogene Abeparvovec Treatment after Nusinersen in an Infant with Spinal Muscular Atrophy Type 1.","authors":"Daiki Nanri, Kotaro Yuge, Kohei Goto, Takuro Kimura, Yukako Yae, Tatsuki Mizuochi, Ryosuke Sato, Tomoyo Itonaga, Tomoki Maeda, Yushiro Yamashita","doi":"10.2739/kurumemedj.MS6934008","DOIUrl":"10.2739/kurumemedj.MS6934008","url":null,"abstract":"Background: Until recently, the treatment of spinal muscular atrophy (SMA) was limited to symptomatic treatment with no cure. Three innovative drugs, nusinersen, onasemnogene abeparvovec (OA), and risdiplam have been developed to treat SMA. Although the clinical trials for these drugs have demonstrated their efficacy, there is limited information on real world treatment strategies. In this study, we present a case of a male infant with SMA type 1 who underwent OA treatment after nusinersen treatment.Case presentation: At 4 months of age, the patient was diagnosed with SMA type 1. At 6 months of age, nusinersen treatment was initiated. His motor function improved, but the effect was limited; therefore, his parents requested gene replacement therapy. During the preparation for OA treatment, anti-adeno-associated virus 9 (AAV9) antibody tests repeatedly showed non-specific reactions, which delayed initiation of treatment. The patient was put on ventilator management after he caught a common cold. During this management, the anti-AAV9 antibody test results were negative. Furthermore, the patient showed increased transaminase levels just before OA treatment; however, since these gradually decreased without signs of liver failure, we started OA treatment at 13 months of age. Four months later, the patient began to sit without support and was weaned from non-invasive positive pressure ventilation, although nasogastric tube feeding remained partially necessary.Conclusion: We believe that the management of unstable SMA type 1 symptoms, anti-AAV9 antibody testing, and changes in transaminase levels will be helpful for other patients with SMA who require treatment.","PeriodicalId":39559,"journal":{"name":"Kurume Medical Journal","volume":" ","pages":"255-259"},"PeriodicalIF":0.0,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139486389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dose Prescription to Isodose Lines in Static Multi-Beam Stereotactic Body Radiotherapy for Lung Tumors: Which Line Is Optimal? 静态多波束立体定向体外放射治疗肺部肿瘤的等剂量线剂量处方：哪条线最佳？

Kurume Medical Journal Pub Date : 2024-05-14 Epub Date: 2024-01-16 DOI: 10.2739/kurumemedj.MS6934016

Maho Iwana-Yamada, Yuta Shibamoto, Fumiya Baba, Hiromitsu Iwata, Satoshi Ishikura, Junpei Nagayoshi, Akio Hiwatashi, Hiroyuki Ogino

{"title":"Dose Prescription to Isodose Lines in Static Multi-Beam Stereotactic Body Radiotherapy for Lung Tumors: Which Line Is Optimal?","authors":"Maho Iwana-Yamada, Yuta Shibamoto, Fumiya Baba, Hiromitsu Iwata, Satoshi Ishikura, Junpei Nagayoshi, Akio Hiwatashi, Hiroyuki Ogino","doi":"10.2739/kurumemedj.MS6934016","DOIUrl":"10.2739/kurumemedj.MS6934016","url":null,"abstract":"This study investigated the appropriate dose prescription method in static multi-beam stereotactic body radiotherapy for lung tumors. Static multi-beam stereotactic body radiotherapy is a mainstream treatment in Japan. Based on the hypothesis that dose prescription to lower isodose lines may improve planning target volume dose coverage and decrease doses to organs at risk, we investigated changes in dose-volume histograms with prescription to various isodose lines for planning target volume in static multi-beam stereotactic body radiotherapy. In all treatment plans, 45 Gy in 4 fractions were prescribed to 95% of the planning target volume. By adjusting the leaf margins of each beam, various prescription isodose lines encompassing 95% volume of the planning target volume were generated. The prescription isodose lines investigated were 40, 50, 60, 70, 80 and 90% lines relative to the maximum dose of each planning target volume. The conformity index, homogeneity index, mean lung dose, and V5-V40 of the lung were evaluated. The dose was calculated by the adaptive convolve algorithm. The conformity index was lowest in the 70% or 80% isodose plan. The mean lung doses and V10-V40 of the lung decreased steeply from the 90% to the 70% isodose plan, and was lowest in the 60% and 70% isodose plans. These indices increased in the 40% and 50% isodose plans. The optimal stereotactic body radiotherapy plans appeared to be dose prescription to the 60% or 70% isodose line. Further investigation is warranted to clarify the advantage of using this method clinically.","PeriodicalId":39559,"journal":{"name":"Kurume Medical Journal","volume":" ","pages":"217-226"},"PeriodicalIF":0.0,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139486265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vulvar Adenoid Cystic Carcinoma with Squamous Cell Carcinoma Component. 带有鳞状细胞癌成分的外阴腺样囊性癌。

Kurume Medical Journal Pub Date : 2024-05-14 Epub Date: 2024-01-16 DOI: 10.2739/kurumemedj.MS6934004

Aya Han, Seiya Kato, Keigo Morinaga, Miki Izumi, Kensuke Kiyokawa

{"title":"Vulvar Adenoid Cystic Carcinoma with Squamous Cell Carcinoma Component.","authors":"Aya Han, Seiya Kato, Keigo Morinaga, Miki Izumi, Kensuke Kiyokawa","doi":"10.2739/kurumemedj.MS6934004","DOIUrl":"10.2739/kurumemedj.MS6934004","url":null,"abstract":"Adenoid cystic carcinoma (ACC) is a major histological type of salivary gland cancer but an uncommon form of vulvar cancer. Salivary gland ACC occasionally dedifferentiates into high-grade carcinoma, resulting in poor prognoses. The dedifferentiated component is usually a poorly differentiated cribriform or solid carcinoma, whereas squamous cell carcinoma (SCC) is exceptional. Herein, we report the case of a 78-year-old woman with vulvar ACC, including an SCC component. She presented with a vulvar nodule that had been present for 30 years and increased in size over the past few years. Magnetic resonance imaging showed a ball-like mass with high intensity on T1-weighted images and high intensity with non-uniformity on T2-weighted images. Considering the systemic and social conditions, the tumor was maximally resected without lymphadenectomy. Histologically, the tumor was composed of a marginal ACC component with a central SCC component. Stage IB vulvar cancer, which was assumed to originate from the Bartholin's gland, was diagnosed. She has survived over 2 years without additional treatments after the surgery. In this case, we assumed that slowly progressive indolent ACC could be dedifferentiated to high- grade SCC. According to our review of available literature, dedifferentiation of vulvar ACC with a high-grade SCC component has not been specifically documented. Although the nature of dedifferentiated vulvar cancer is unclear, it should be noted that high-grade dedifferentiation can occur in long-lasting vulvar masses.","PeriodicalId":39559,"journal":{"name":"Kurume Medical Journal","volume":" ","pages":"251-254"},"PeriodicalIF":0.0,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139486449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of Pemafibrate on Reducing Oxidative Stress and Augmenting Angiogenesis in Ischemic Limb Tissue. 培马贝特对减轻缺血肢体组织氧化应激和促进血管生成的影响

Kurume Medical Journal Pub Date : 2024-05-14 Epub Date: 2024-01-16 DOI: 10.2739/kurumemedj.MS6934006

Tomoyuki Anegawa, Ken-Ichiro Sasaki, Yuta Ishizaki, Shinya Negoto, Atsunobu Oryoji, Eiji Nakamura, Hiroyuki Otsuka, Shinichi Hiromatsu, Yoshihiro Fukumoto, Eiki Tayama

{"title":"Effects of Pemafibrate on Reducing Oxidative Stress and Augmenting Angiogenesis in Ischemic Limb Tissue.","authors":"Tomoyuki Anegawa, Ken-Ichiro Sasaki, Yuta Ishizaki, Shinya Negoto, Atsunobu Oryoji, Eiji Nakamura, Hiroyuki Otsuka, Shinichi Hiromatsu, Yoshihiro Fukumoto, Eiki Tayama","doi":"10.2739/kurumemedj.MS6934006","DOIUrl":"10.2739/kurumemedj.MS6934006","url":null,"abstract":"Objective: Oxidative damage is observed in the ischemic limbs of patients with arteriosclerosis obliterans. We investigated whether pemafibrate, a selective peroxisome proliferator-activated receptor alpha modulator, reduced oxidative stress in ischemic limbs and consequently rescued limb damage in model mice.Materials and methods: We surgically induced hind-limb ischemia in mice and orally administered pemafibrate solution (P-05 group, 0.5 mg/kg/day; P-10 group, 1.0 mg/kg/day) or control solution (control group). Seven days after the surgery, differences in reactive oxygen species (ROS) contents, antioxidative enzyme and transcription factor expression, blood flow, and capillary density in ischemic limbs were assessed.Results: Tissue ROS levels were lower in the P-05 and P-10 groups compared with those in the control group. Although the tissue expression levels of nuclear factor-erythroid 2-related factor 2 increased in the P-10 group compared with that in the control group, no corresponding changes were observed in the tissue expression of four antioxidative enzymes. The limb salvage rates and capillary densities in ischemic limbs were higher in the P-05 and P-10 groups than that in the control group.Conclusion: Pemafibrate treatment reduced oxidative stress and augmented angiogenesis in ischemic limbs, contributing to prevention of limb damage in mice.","PeriodicalId":39559,"journal":{"name":"Kurume Medical Journal","volume":" ","pages":"167-174"},"PeriodicalIF":0.0,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139486272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk Factors in Fetal Ovarian Cysts for Postnatal Adverse Outcomes. 胎儿卵巢囊肿导致产后不良后果的风险因素。

Kurume Medical Journal Pub Date : 2024-05-14 Epub Date: 2024-01-16 DOI: 10.2739/kurumemedj.MS6934002

Megumi Muto, Toshiyuki Yoshizato, Takashi Horinouchi, Masato Yokomine, Yoshitaka Sakamoto, Shinji Ishii, Masahiro Kinoshita, Yutaka Kozuma, Kimio Ushijima

{"title":"Risk Factors in Fetal Ovarian Cysts for Postnatal Adverse Outcomes.","authors":"Megumi Muto, Toshiyuki Yoshizato, Takashi Horinouchi, Masato Yokomine, Yoshitaka Sakamoto, Shinji Ishii, Masahiro Kinoshita, Yutaka Kozuma, Kimio Ushijima","doi":"10.2739/kurumemedj.MS6934002","DOIUrl":"10.2739/kurumemedj.MS6934002","url":null,"abstract":"Aim: To investigate the natural history of fetal ovarian cysts and elucidate the risk factors for postnatal adverse outcomes in fetal ovarian cysts.Methods: The study subjects were 18 cases with ovarian cysts prenatally diagnosed using ultrasonography at our hospital between 2007 and 2020. The subjects were classified by cyst characteristics according to echogenic patterns [simple cyst (S) and complex cyst (C)], changes in echogenic patterns (S-to-S, S-to-C, and C-to-C), and diameters (<40 and ≥ 40 mm). Clinical parameters and outcomes were compared between S and C patterns, S-to-S and S-to-C patterns, and <40 and ≥ 40 mm diameters.Results: Cases with S and C patterns (15 and 3, respectively) had median gestational ages of 35 and 36 weeks, respectively, and maximum cyst diameters of 36 and 57mm, respectively. The number of cases with S-to-S, S-to-C and C-to-C patterns were 11, 4 and 3, respectively. The maximum cyst diameter in cases with S-to-C patterns (58 mm) was larger than that in cases with S-to-S patterns (34 mm) (P<0.05). Placental weight in cases with cysts >40 mm and/or cyst expansion was greater than that in cases with neither or both conditions (P<0.05). Spontaneous resolution (before and after birth) occurred in 8 of 9 and 3 of 9 cases with maximum cyst diameters <40 and ≥ 40 mm, respectively. Ovarian function was lost in 2 cases with S-to-C patterns and in 2 cases with C-to-C patterns.Conclusion: Cases with cyst diameters ≥ 40 mm and/or cyst expansion during the late third trimester had greater placental weight and more postnatal adverse outcomes.","PeriodicalId":39559,"journal":{"name":"Kurume Medical Journal","volume":" ","pages":"127-133"},"PeriodicalIF":0.0,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139486435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combination of Prednisolone and Calcineurin Inhibitors Prevents Lung Function Decline in Patients with Anti-aminoacyl-tRNA Synthetase Antibody-Positive Polymyositis/Dermatomyositis. 强的松龙联合钙调磷酸酶抑制剂预防抗氨基酰基trna合成酶抗体阳性的多发性肌炎/皮肌炎患者肺功能下降

Kurume Medical Journal Pub Date : 2023-11-30 Epub Date: 2023-08-07 DOI: 10.2739/kurumemedj.MS6912002

Yuki Yorishima, Masaki Tominaga, Kiminori Fujimoto, Shuji Nagata, Akiko Sumi, Tomonori Chikasue, Masaki Okamoto, Shinjiro Kaieda, Goushi Matama, Yoshiaki Zaizen, Hitoshi Obara, Tatsuyuki Kakuma, Hiroaki Ida, Tomotaka Kawayama, Tomoaki Hoshino

{"title":"Combination of Prednisolone and Calcineurin Inhibitors Prevents Lung Function Decline in Patients with Anti-aminoacyl-tRNA Synthetase Antibody-Positive Polymyositis/Dermatomyositis.","authors":"Yuki Yorishima, Masaki Tominaga, Kiminori Fujimoto, Shuji Nagata, Akiko Sumi, Tomonori Chikasue, Masaki Okamoto, Shinjiro Kaieda, Goushi Matama, Yoshiaki Zaizen, Hitoshi Obara, Tatsuyuki Kakuma, Hiroaki Ida, Tomotaka Kawayama, Tomoaki Hoshino","doi":"10.2739/kurumemedj.MS6912002","DOIUrl":"10.2739/kurumemedj.MS6912002","url":null,"abstract":"Objective: Anti-aminoacyl-tRNA synthetase antibody-positive polymyositis/dermatomyositis-associ ated interstitial lung disease (ARS-ILD) has a good prognosis, with few cases progressing to respiratory failure. This study aimed to determine factors predictive of lung function changes in patients with ARS-ILD.Methods: We retrospectively studied 49 patients with ARS-ILD treated at Kurume University Hospital Hospital between 2000 and 2018. We followed 30 patients for more than 2 years after prednisolone (PSL) therapy, with or without calcineurin inhibitors (CNIs), evaluating clinical, physiological, computed tomography, pulmonary func tion, and serological data.Results: After treatment for 24 months, no significant differences were noted between clinical parameters and improvement in forced vital capacity (FVC), %FVC, % carbon monoxide diffusing capacity/alveolar volume (%DLCO), and %DLCO/alveolar volume. Conversely, the annual change of %FVC significantly correlated with the Medical Research Council dyspnea scale grade and %FVC at the first visit and treatment. Furthermore, the annual change of %DLCO/VA significantly correlated with the duration from the first visit to treatment initiation.Conclusion: Compared with PSL monotherapy, combining PSL and CNI showed greater mitigation of %FVC decline. The time from onset of ARS-ILD to the first visit is critical for preventing a decline in lung function, and as such, patients should be monitored carefully.","PeriodicalId":39559,"journal":{"name":"Kurume Medical Journal","volume":" ","pages":"19-30"},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10000127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Outcomes of Radiation Therapy for Choroidal Metastases and A Literature Review. 脉络膜转移瘤放射治疗的临床疗效及文献综述。

Kurume Medical Journal Pub Date : 2023-11-30 Epub Date: 2023-10-03 DOI: 10.2739/kurumemedj.MS69120012

Masanari Niwa, Natsuo Tomita, Akifumi Miyakawa, Shiho Ayakawa, Natsuko Takama, Akira Torii, Nozomi Kita, Satoshi Ishikura, Yuta Shibamoto

{"title":"Clinical Outcomes of Radiation Therapy for Choroidal Metastases and A Literature Review.","authors":"Masanari Niwa, Natsuo Tomita, Akifumi Miyakawa, Shiho Ayakawa, Natsuko Takama, Akira Torii, Nozomi Kita, Satoshi Ishikura, Yuta Shibamoto","doi":"10.2739/kurumemedj.MS69120012","DOIUrl":"10.2739/kurumemedj.MS69120012","url":null,"abstract":"Introduction: Radiation therapy (RT) for choroidal metastasis (CM) aims to preserve vision and achieve local control (LC), thereby maintaining quality of life. The present study reports the clinical outcomes of RT for CM and reviews the literature.Methods: We retrospectively collected data on 11 patients with CM; their primary tumors were breast cancer (n=3), lung cancer (n=3), leukemia (n=2), lymphoma (n=2), and gastric cancer (n=1). Four patients had bilateral CM. The median radiation dose was 39 Gy in 13 fractions (range, 20-50 Gy in 10-25 fractions). We investigated changes in visual acuity, tumor responses, morbidities, LC, and overall survival (OS). A systematic review of literature published between 1990 and 2020 was performed using the PubMed database.Results: One, 1, and 6 patients had improved, stabilized, and worse visual acuity, respectively (data missing for 3 patients). Nevertheless, eight patients considered their visual acuity to have improved or remained the same after RT. Among 15 lesions in 11 patients, complete and partial responses were observed in 2 and 6, respectively (data missing for 7 lesions in 4 patients). Three-year LC and OS rates were 100 and 32%, respectively. Grade ≥ 3 morbidities were not observed. In the literature review, the most common primary cancer was breast cancer followed by lung cancer. Improvements in or the stabilization of visual acuity was observed in 80% of patients (range, 47-100), and the median survival time was 11 months (range, 4.9-23).Conclusion: RT is an efficient and safe palliative treatment for CM without severe toxicity.","PeriodicalId":39559,"journal":{"name":"Kurume Medical Journal","volume":" ","pages":"89-97"},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41154105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High-Flow Nasal Oxygen for Severe COVID-19 Pneumonia in Greek Patients: A Prospective Observational Study. 希腊患者重度新冠肺炎肺炎的高-低鼻氧治疗：一项前瞻性观察研究。

Kurume Medical Journal Pub Date : 2023-11-30 Epub Date: 2023-10-03 DOI: 10.2739/kurumemedj.MS69120013

Petros Ioannou, Ioannis Akoumianakis, Theodosios D Filippatos, Evangelia Akoumianaki, Georgios Chamilos, Diamantis P Kofteridis

{"title":"High-Flow Nasal Oxygen for Severe COVID-19 Pneumonia in Greek Patients: A Prospective Observational Study.","authors":"Petros Ioannou, Ioannis Akoumianakis, Theodosios D Filippatos, Evangelia Akoumianaki, Georgios Chamilos, Diamantis P Kofteridis","doi":"10.2739/kurumemedj.MS69120013","DOIUrl":"10.2739/kurumemedj.MS69120013","url":null,"abstract":"Introduction: High-flow nasal oxygen (HFNO) and prone positioning may improve outcomes of coronavirus disease 2019 (COVID-19) patients treated in the intensive care unit (ICU). The aim of this study was to describe outcomes following the timely application of HFNO and prone positioning in COVID-19 patients treated in a ward setting.Methods: The study included 89 prospectively recruited subjects at the COVID-19 ward unit of the University Hospital of Heraklion, Greece, between March and December 2020.Results: Seventy-four (83%) of the 89 subjects in the study had severe COVID-19. Of those, 33 (45%) required HFNO treatment and prone positioning and 15 (45%) were transferred to the ICU, with 4 of them being intubated. Severe COVID-19 and HFNO needs were associated with an increased pneumonia severity index (PSI) score on admission and a worse PaO2/FiO2 ratio. In multivariate analysis, PSI was the only independent predictor of subsequent HFNO needs (OR=1.022). Overall intubation and mortality rates were 5.6% and 3.4%, respectively.Conclusion: This study shows that for patients with severe COVID-19 hospitalized in medical wards, standard COVID-19 treatment, along with the timely utilization of HFNO and prone positioning, resulted in excellent outcomes with fewer ICU admission rates.","PeriodicalId":39559,"journal":{"name":"Kurume Medical Journal","volume":" ","pages":"53-63"},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41161488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of Nivolumab and Ipilimumab Combined Therapy as a First-Line Therapy for Patients with Advanced Melanoma and the Urgent Need for an Effective Second-Line Therapy for Patients with Wild-Type BRAF in Japan: A Single Center Retrospective Study. Nivolumab和Ipilimumab联合治疗晚期黑色素瘤患者的一线疗效和日本野生型BRAF患者急需有效的二线治疗：一项单中心回顾性研究。

Kurume Medical Journal Pub Date : 2023-11-30 Epub Date: 2023-10-03 DOI: 10.2739/kurumemedj.MS6912008

Ikko Muto, Hiroshi Koga, Reiichi Doi, Eri Katayama, Kenta Nakama, Takekuni Nakama

{"title":"Efficacy of Nivolumab and Ipilimumab Combined Therapy as a First-Line Therapy for Patients with Advanced Melanoma and the Urgent Need for an Effective Second-Line Therapy for Patients with Wild-Type BRAF in Japan: A Single Center Retrospective Study.","authors":"Ikko Muto, Hiroshi Koga, Reiichi Doi, Eri Katayama, Kenta Nakama, Takekuni Nakama","doi":"10.2739/kurumemedj.MS6912008","DOIUrl":"10.2739/kurumemedj.MS6912008","url":null,"abstract":"Therapeutic advantages of immune checkpoint inhibitors, anti-programmed death-1 (PD-1), and anticytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) in melanoma have been reported recently. In this study, we conducted a retrospective study to evaluate the clinical efficacy and safety of the combined use of nivolumab and ipilimumab as a first-line therapy for Japanese patients with advanced melanoma. Moreover, we examined the effects of second-line treatment. Seven patients were enrolled in this study. The median progression-free survival (PFS) and median overall survival (OS) were 7 months (95%CI, 1.868-12.132) and 12 months (95%CI, 0.000- 27.397), respectively. The objective response rate (ORR) and the disease control rate (DCR) were 42.9 % and 85.7 %. Three patients chose pembrolizumab monotherapy as second-line therapy after the combination therapy due to their BRAF wild-type status, which resulted in progressive disease. ORR and DCR were 0% and 33.3%, respectively, with pembrolizumab. Grade 3 or 4 immune-related adverse events occurred in 71.4% of the patients treated with the combined-therapy. All irAEs were treated with corticosteroid or hormone replacement therapy. Although this single center retrospective study had some limitations, it demonstrated good efficacy for the combined use of nivolumab and ipilimumab as a first-line therapy for Japanese patients with advanced melanoma. Moreover, poor efficacy was observed for the second-line therapy after the combined therapy. These findings suggest that a novel second-line therapy is required for patients with advanced melanoma in Japan, particularly for patients with wildtype BRAF.","PeriodicalId":39559,"journal":{"name":"Kurume Medical Journal","volume":" ","pages":"75-80"},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41139005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0